Young, R J <br/><br/>
Analysis of circulating angiogenic biomarkers from patients in two phase III trials in lung cancer of chemotherapy alone or chemotherapy and thalidomide.  [electronic resource] 

 -  British journal of cancer  Mar 2012 
 - 1153-9 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1532-1827 
<br/><br/><label>Standard No.: </label>10.1038/bjc.2012.50  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Angiogenesis Inhibitors--therapeutic use<br/>Antineoplastic Combined Chemotherapy Protocols--therapeutic use<br/>Biomarkers, Tumor--blood<br/>Carboplatin--administration & dosage<br/>Carcinoma, Non-Small-Cell Lung--blood<br/>Clinical Trials, Phase III as Topic<br/>Deoxycytidine--administration & dosage<br/>Etoposide--administration & dosage<br/>Female<br/>Fibroblast Growth Factor 2--blood<br/>Humans<br/>Intercellular Adhesion Molecule-1--blood<br/>Interleukin-8--blood<br/>Lung Neoplasms--blood<br/>Male<br/>Middle Aged<br/>Multicenter Studies as Topic<br/>Multivariate Analysis<br/>Neovascularization, Pathologic--blood<br/>Proportional Hazards Models<br/>Randomized Controlled Trials as Topic<br/>Small Cell Lung Carcinoma--blood<br/>Survival Analysis<br/>Thalidomide--therapeutic use<br/>Treatment Outcome<br/>Vascular Endothelial Growth Factor A--blood<br/>Gemcitabine